capital raise

Clinical-stage biotech Spyre Therapeutics launches $300M public offering to fund inflammatory bowel disease drug development, with major investment banks leading.

Clinical-stage biotech Spyre Therapeutics announced $300M public offering with $45M underwriter option, led by Jefferies and Goldman Sachs, targeting IBD treatments.

One and One Green Technologies closed $13M follow-on offering at $7.50/unit. Company raises capital for working capital and operations.

CoreWeave stock surged 8.37% Monday as four analysts raised price targets, citing Meta's $21B deal and Anthropic partnership alongside successful pricing increases.

$LNKS completes full exercise of Series B warrants using zero-price option following 250-for-1 reverse split, restructuring capital base.

Vertical Aerospace secures $850M from Mudrick Capital and Yorkville Advisors, including $50M equity and $750M optional financing, shifting focus from survival to execution on eVTOL development.

Celldex Therapeutics closed $345M public offering at $29/share with full underwriter option exercise, netting approximately $401M in total gross proceeds.

Nebius stock surged 13.8% in March following Nvidia's $2 billion investment, Meta's $27 billion AI infrastructure deals, and $4 billion in convertible notes for expansion.

Fireweed Metals closes $61.5M private placement at $4.18/share with JX Advanced Metals taking 5% stake, providing capital for Yukon project development.

Celldex prices $300M stock offering at $29/share to fund commercial launch of CSU treatment and expand bispecific antibody platform.

Tantech Holdings ($TANH) completed $2.15M registered direct offering, issuing 7.17M units at $0.30 each for corporate and working capital needs.

Artelo Biosciences closes $11M private placement at $3.45/share, raising capital for operations and debt repayment with additional warrant upside.

Planet Labs stock fell 9.7% after announcing warrant redemption causing ~4% shareholder dilution. The decline appears disproportionate to the modest and expected dilution impact.

Xenon Pharmaceuticals' CMO sold $78K in shares via routine vesting, as stock surges 55% following positive Phase 3 trial results and $750M capital raise.

Zenas BioPharma prices $300M offering combining $200M convertible notes and 5M common shares to fund obexelimab launch and pipeline advancement.

SK Hynix plans confidential U.S. IPO in H2 2026 to raise up to $14 billion for new chip factories, targeting booming AI data center demand amid intense competition.

Apogee Therapeutics prices $350M offering at $70/share to fund development of inflammatory disease treatments, with lead candidate Zumilokibart targeting atopic dermatitis.

Harrow prices $50M in senior unsecured notes due 2030, expanding existing debt facility for product development and strategic initiatives.

Paranovus Entertainment raises $5M via direct offering of 14.3M shares at $0.35 each, closing March 25, 2026.

Abivax CEO dismisses acquisition rumors, plans equity and debt raise after Phase 3 obefazimod data in Q2 2026. $614.42M cash runway supports strategy.